Bellevue Group’s Ventyx Biosciences VTYX Stock Holding History

Bellevue Group’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-24,500	Closed	-$851K	–	175
2023 Q3	$851K	Hold	24,500	–	–	0.01%	132
2023 Q2	$804K	Sell	24,500 -1,000	-4%	-$34.5K	0.01%	135
2023 Q1	$854K	Buy	+25,500	New	+$992K	0.01%	131

Other funds holding VTYX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bellevue Group's VTYX Position: Q4 2023 in Review

Bellevue Group sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 24,500 shares — an estimated $851K sold.

Bellevue Group first reported a position in VTYX in Q1 2023 and held it in 3 quarters. The position peaked at $854K in Q1 2023. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

Bellevue Group reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
Bellevue Group sold 24,500 Ventyx Biosciences shares in Q4 2023, an estimated $851K.
Bellevue Group first reported a position in Ventyx Biosciences in Q1 2023 and held it in 3 quarters.
Bellevue Group's Ventyx Biosciences position peaked at $854K in Q1 2023.
121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.